News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma
Photo from Miao-Zhen Qiu/LinkedIn
Jun 18, 2024, 07:07

Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

“Tislelizumab plus chemotherapy vs chemotherapy alone in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma.

RATIONALE-305

  • Median overall survival (mOS) in the intention-to-treat (ITT) population: 15 months versus 12.9 months, with a hazard ratio (HR) of 0.80 (95% CI 0.70 to 0.92); P=0.001.
  • Median overall survival (mOS) in the population with PD-L1 Tumor Proportion Score (TPS) ≥5%: 16.4 months versus 12.8 months, HR: 0.71 (95% CI 0.58 to 0.86).”

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Authors: Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, and Rui-Hua Xu.

RATIONALE-305

Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinomaSource: Erman Akkus/X

Adenocarcinoma advanced gastric adenocarcinoma Anastasia V Zimina cancer chemotherapy David Spigel Do-Youn Oh Elena Poddubskaya Erman Akkus first-line treatment Gastroesophageal Junction Adenocarcinoma Hidekazu Hirano Hongming Pan Hongwei Wang Jiang Li Jianhua Shi Josep Tabernero Jufeng Wang Ken Kato Kensei Yamaguchi Keun-Wook Lee Liyun Li Lorenzo Fornaro Lucjan Wyrwicz Ludovic Evesque Marcia Cruz-Correa Markus Moehler median overall survival Miao-Zhen Qiu mOS OncoDaily Oncology RATIONALE-305 Roberto Pazo Cid Rui-Hua Xu Ruixing Zhang Silu Yang Sun Young Rha Tao Sheng Tislelizumab Tobias Arkenau Umut Disel Yaling Xu Yee Chao Yuxian Bai
Special Coverage
Blog
Nov 13, 2024, 14:05
Tala Mahmoud: Honored to be selected as Reviewer of the Month by ACGCRJ
Blog
Nov 13, 2024, 12:13
Sarah Briggs: Cancer control in the face of climate change
Blog
Nov 13, 2024, 11:56
HER2-Low Status and Its Impact on Outcomes in Early-Stage Triple-Negative Breast Cancer
Blog
Nov 13, 2024, 11:52
Andrew Pannu: Analysis of Big Pharma Therapeutic M&A Deals from 2019 to today
Blog
Nov 13, 2024, 11:48
Indoor cooking with solid fuels can increase lung cancer risk - IASLC
Blog
Nov 13, 2024, 11:44
Registration for the AACR Annual Meeting 2025 is now open
Blog
Nov 13, 2024, 11:39
i4KIDS I i4KIDS-EUROPE - Ship2B Ventures Impact Forum
Blog
Nov 13, 2024, 11:34
Erika Hamilton: Inspired by the strength of the veteran patients and their commitment to continue fighting
Blog
Nov 13, 2024, 11:30
ABC Global Alliance - Learning more about brain metastases in breast cancer
Blog
Nov 13, 2024, 11:25
Some information you should know about lung cancer - American Cancer Society
Insight
Nov 13, 2024, 11:10
Myeloma Paper of the Day, November 13th, suggested by Robert Orlowski
Blog
Nov 13, 2024, 11:01
LGCW2024 session on Galvanising African cancer research building a strong cancer workforce - AORTIC- Africa